Ropes & Gray advised Eli Lilly on Collaboration With Repertoire Immune Medicines

Ropes & Gray Advised Eli Lilly on Collaboration With Repertoire Immune Medicines

Ropes & Gray advised Eli Lilly and Company (Lilly) in a strategic collaboration with Repertoire Immune Medicines, a biotechnology company that develops programmable T cell target immune medicines, to develop tolerizing therapies for multiple autoimmune diseases. The collaboration announced on January 29 aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression common in available therapies.

Under the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 billion for achieving certain development and commercial milestones and tiered royalties on net sales.

The Ropes & Gray team was led by life sciences licensing Abby Gregor (Partner) and life sciences transactions Ray Grant (Partner).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.